

# Improving our understanding of factors influencing patient outcomes in pleural disease

|  |  |  |
|--|--|--|
| <b>Submission date</b><br>10/01/2023   | <b>Recruitment status</b><br>Recruiting  | <input checked="" type="checkbox"/> Prospectively registered<br><input checked="" type="checkbox"/> Protocol |
| <b>Registration date</b><br>20/03/2023 | <b>Overall study status</b><br>Ongoing   | <input type="checkbox"/> Statistical analysis plan<br><input type="checkbox"/> Results                       |
| <b>Last Edited</b><br>06/11/2024       | <b>Condition category</b><br>Respiratory | <input type="checkbox"/> Individual participant data<br><input type="checkbox"/> Record updated in last year |

## Plain English summary of protocol

### Background and study aims

The pleural membranes are two thin layers of tissue covering the outside of the lungs, which are vulnerable to different diseases including, pleural effusions, where excess fluid accumulates in the space between the lung and the chest wall (the pleural space); pneumothorax, where the pleural space fills with air causing the lung to collapse; pleural cancer (mesothelioma), this is usually associated with asbestos exposure; and, pleural thickening, where the lining around the lung becomes scarred, often because it has been inflamed in the past. All of these conditions can cause breathlessness, which can be severe. Unfortunately, a general lack of research means there are many unanswered questions regarding how best to diagnose and manage pleural diseases. There is often no single test that can provide us with a diagnosis, and patients frequently need multiple procedures to diagnose their condition and manage symptoms. We plan to create a new, long-term study to collect data on patients with pleural disease, to improve our understanding of how to diagnose and manage their condition, and the impact their disease and its management have on their quality of life.

### Who can participate?

Any patient presenting to North Bristol's tertiary pleural service with confirmed effusion, pneumothorax or pleural thickening, who is over the age of 16 and lives within reach of the service

### What does the study involve?

The team will invite every patient who attends Southmead hospital with a pleural condition to take part in a simple follow-up study. Data will be recorded about participants' health, and store small amounts of routinely collected blood, fluid and tissue for future laboratory tests. These samples will be used to apply more cutting-edge tests as they become available, which may improve the ability to diagnose the underlying cause of pleural disease. This study does not require any additional visits to the hospital in addition to routine care. Patients will also be asked to fill out brief questionnaires at enrolment, 4 months and 12 months after enrolling about how they are affected by their condition.

### What are the possible benefits and risks of participating?

There are no direct clinical benefits to participants from engaging in this research as it is

observational. Once the results are published, it is hoped that the knowledge obtained will benefit patients in the future by helping clinicians understand better how to manage patients with this condition, taking into account different factors that may influence their outcomes. The observational nature of the study means that there are no additional risks to patients from participating.

Where is the study run from?

The lead site is North Bristol NHS Trust, Southmead Hospital (UK)

When is the study starting and how long is it expected to run for?

June 2021 to March 2029

Who is funding the study?

1. Rocket Medical Plc (UK)
2. Southmead Hospital Charity (UK)
3. National Institute for Health and Care Research (NIHR) (UK)

Who is the main contact?

Dr Eleanor Barton, [eleanor.barton@nbt.nhs.uk](mailto:eleanor.barton@nbt.nhs.uk) (UK)

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-looking-at-new-ways-to-diagnose-and-monitor-people-with-diseases-of-the-lung-lining>

## Contact information

### Type(s)

Scientific

### Contact name

Dr Eleanor Barton

### ORCID ID

<https://orcid.org/0000-0003-0381-810X>

### Contact details

Pleural Clinical Research Fellow  
Academic Respiratory Unit  
North Bristol NHS Trust  
Southmead Hospital  
Bristol  
United Kingdom  
BS10 5NB  
+44 (0)117 414 8033  
[eleanor.barton@nbt.nhs.uk](mailto:eleanor.barton@nbt.nhs.uk)

## Additional identifiers

### Clinical Trials Information System (CTIS)

Nil known

## **Integrated Research Application System (IRAS)**

319757

## **ClinicalTrials.gov (NCT)**

Nil known

## **Protocol serial number**

CPMS 54190, IRAS 319757

# **Study information**

## **Scientific Title**

Severn Pleural Disease Outcomes: Long Term Insights Study

## **Acronym**

SPOTLight

## **Study objectives**

The aim of this long-term observational study is to improve our understanding of the long-term, patient-reported outcomes of pleural disease.

## **Ethics approval required**

Old ethics approval format

## **Ethics approval(s)**

Approved 24/02/2023, Wales REC 6 (Public Health Wales, Building 1, Jobswell Road, St David's Park, SA31 3HB, UK; +44 1267 61 1164; Wales.REC6@wales.nhs.uk), ref: 23/WA/0018

## **Study design**

Single-centre longitudinal prospective observational cohort study

## **Primary study design**

Observational

## **Study type(s)**

Treatment

## **Health condition(s) or problem(s) studied**

Respiratory

## **Interventions**

Patients presenting with radiologically confirmed pleural disease including (but not limited to) pneumothorax, pleural effusion, pleural thickening or pleural cancer (mesothelioma) to North Bristol NHS Trust will be screened and invited to participate by a member of the study team. The team will collect data on the patient's demographics, past medical history and history of current illness, smoking status including cannabis, asbestos and other inhalational exposures, clinical frailty score (CFS) and performance status (PS). The team will also collect data related to their condition and its management, for example, radiological and thoracic ultrasound appearances, the number and type of interventions undertaken and digital measurements of air leaks in the case of pneumothorax. For patients with pleural effusions, if blood or pleural fluid

samples are collected as part of their routine care, additional research samples will also be collected for use in current or future studies. For patients who undergo a pleural biopsy procedure following enrolment, additional tissue samples may be obtained and retained for research purposes if felt appropriate by the operator. These data and sample collections are not study-specific procedures but are performed as part of the participants' routine clinical care. At enrolment and 4- and 12-months post-enrolment, patients will be asked to complete 2 routine questionnaires to provide patient-reported outcome measures. These are study-specific, not part of the patient's routine care. Where necessary, additional PROMS relevant to a specific sub-study the patient may be eligible for may also be collected during the baseline assessment. These will be undertaken at the initial assessment, and either remotely, or during the routine clinical review at 4 and 12 months.

Further data will be collected from the patient's medical records at 4 months and 12 months post enrolment, to encompass the patient's length of stay, number and type of interventions, and mortality. These two timepoints allow for the collection of complete data sets, acknowledging that some patients may have a prolonged diagnostic pathway or require recurrent procedures to manage their symptoms. A final diagnosis will be recorded after 12 months, based on the diagnosis of their treating clinician, and ratified by a second pleural specialist.

### **Intervention Type**

Other

### **Primary outcome(s)**

1. Breathlessness and pain measured using the patient-reported outcome measures (PROMs) Visual Analogue Scale (VAS) at baseline, 4 months and 12 months
2. Health-related quality of life measured using the EuroQol 5D Health Questionnaire (EQ-5D-5L) at baseline, 4 months and 12 months

### **Key secondary outcome(s)**

There are no secondary outcome measures

### **Completion date**

01/03/2029

## **Eligibility**

### **Key inclusion criteria**

1. Confirmed presence (radiologically) of either:
  - 1.1. Pleural effusion/pleural thickening OR
  - 1.2. Spontaneous primary or secondary pneumothorax
2. Patient normally lives within the catchment area of the Bristol hospitals and is unlikely to relocate within 12 months
3. Aged 16 years old and over
4. Has access to telephone and/or internet

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

16 years

**Sex**

All

**Key exclusion criteria**

To be eligible to participate in the cohort, none of the following criteria should apply:

1. Previously enrolled in SPOTLight
2. Patient (or appropriate proxy) is not able to provide written informed consent
3. Patient is in the final stages of life or sufficiently frail to make study involvement inappropriate

**Date of first enrolment**

02/05/2023

**Date of final enrolment**

02/05/2028

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre****Southmead Hospital**

Southmead Road

Westbury-on-trym

Bristol

United Kingdom

BS10 5NB

**Sponsor information****Organisation**

North Bristol NHS Trust

**ROR**

<https://ror.org/036x6gt55>

# Funder(s)

## Funder type

Government

## Funder Name

National Institute for Health and Care Research

## Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

## Funding Body Type

Government organisation

## Funding Body Subtype

National government

## Location

United Kingdom

## Funder Name

Rocket Medical plc

## Funder Name

North Bristol NHS Trust

## Alternative Name(s)

NBT

## Funding Body Type

Government organisation

## Funding Body Subtype

Local government

## Location

United Kingdom

# Results and Publications

Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at a later date

### IPD sharing plan summary

Data sharing statement to be made available at a later date

### Study outputs

| Output type                                   | Details                       | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|-------------------------------|--------------|------------|----------------|-----------------|
| <a href="#">HRA research summary</a>          |                               |              | 26/07/2023 | No             | No              |
| <a href="#">Participant information sheet</a> | Participant information sheet | 11/11/2025   | 11/11/2025 | No             | Yes             |
| <a href="#">Protocol file</a>                 | version 1.0                   | 16/11/2022   | 16/01/2023 | No             | No              |